This review emphasizes the importance of pharmacological interventions targeting high mobility group box 1 (HMGB1)-mediated brain damage after subarachnoid hemorrhage (SAH) and CVS. This evidence concerns the gene HMGB1 and subarachnoid hemorrhage.